Skip to main content
Clinical Trials/NCT06007066
NCT06007066
Completed
Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-controlled Phase II Study of The Efficacy And Safety of HSK16149 In The Treatment of Patients With Orthopedic Perioperative Analgesia

Haisco Pharmaceutical Group Co., Ltd.21 sites in 1 country235 target enrollmentMarch 8, 2023

Overview

Phase
Phase 2
Intervention
HSK16149 capsule
Conditions
Post-operative Pain
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Enrollment
235
Locations
21
Primary Endpoint
Morphine Consumption
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study will compare the effect and safety of HSK16149 with placebo on perioperative analgesia in orthopedic surgery, and explore the dosage of HSK16149 capsules for orthopedic analgesia during perioperative period.

Detailed Description

This study included patients who have orthopedic surgery under general anesthetic, with expected operation time ≤4h. Subjects were given 40mg or 60mg of HSK16149 or placebo orally the night before surgery, 2h before surgery, 4h and 16h after surgery, for a total of 4 times during the whole treatment period. Subjects will receive intravenous patient-controlled analgesia (PCA) morphine for pain in the immediate postoperative period. If PCA is insufficient, rescue analgesia of morphine may be given I.V. as determined by the investigator. After the treatment period, the subjects will be followed up.

Registry
clinicaltrials.gov
Start Date
March 8, 2023
End Date
July 5, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female between the ages of 18 and 75 years (included);
  • Elective orthopedic surgery under general anesthesia, expected operation time ≤4 hours and postoperative morphine analgesia time ≥24 hours;
  • 18kg/m\^2≤BMI≤30 kg/m\^2;
  • American Society of Anesthesiologists (ASA) grade I and II;

Exclusion Criteria

  • Any of the following medical histories or conditions prior to screening:
  • Long history of chronic pain;
  • history of severe cardiovascular or respiratory disease;
  • history of neurological or psychiatric disorders;
  • history of acute poisoning with alcohol, hypnotics, analgesics or other drugs acting on the central nervous system;
  • major surgery within 3 months;
  • patients with high bleeding risk;
  • history of renal disease treated with dialysis within 28 days before surgery;
  • have active infection within the past 2 weeks;
  • Use of any of the following medications or treatments:

Arms & Interventions

Preoperative administration of HSK16149 40mg

HSK16149 40mg will be administered the night before and 2h before surgery

Intervention: HSK16149 capsule

Preoperative administration of HSK16149 60mg

HSK16149 60mg will be administered the night before and 2h before surgery

Intervention: HSK16149 capsule

Preoperative and postoperative administration of HSK16149 40mg

HSK16149 40mg will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery

Intervention: HSK16149 capsule

Preoperative and postoperative administration of HSK16149 60mg

HSK16149 60mg will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery

Intervention: HSK16149 capsule

placebo

The placebo will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery

Intervention: Placebo

Outcomes

Primary Outcomes

Morphine Consumption

Time Frame: Participants received PCA pump, an average of 24 hours after surgery

IV Patient Controlled Analgesia (PCA) morphine for pain management in the immediate postoperative period for an average of 24 hours after surgery. If PCA is insufficient, rescue analgesia of morphine may be given I.V. as determined by the investigator. Total morphine consumption = PCA morphine consumption + rescue analgesia morphine consumption.

Secondary Outcomes

  • NRS at rest and during exercise(1, 2, 6, 12, 18, and 24 hours after surgery)
  • Daily Sleep Interference Scale (DSIS)(Within 24 hours after surgery)
  • The frequency of rescue analgesia with morphine(Within 24 hours after surgery)
  • The total number of PCA presses and the number of effective PCA presses(Within 24 hours after surgery)
  • Investigators analgesic satisfaction score(Within 24 hours after surgery)
  • Incidence of adverse reactions associated with morphine(Within 24 hours after surgery)
  • Subjects analgesic satisfaction score(Within 24 hours after surgery)
  • Number of participants with treatment-related adverse events(TEAE) as assessed by CTCAE v5.0.(From enrollment to 72 hours after surgery)
  • Time of first rescue analgesia with morphine after surgery(Within 24 hours after surgery)

Study Sites (21)

Loading locations...

Similar Trials